Concepedia

Hans Jaeger

HJ

Statistics

Publications

11

Citations

892

H-Index

11

Active since

1988

Affiliations

MUC Research (Germany)(Current)

Harvard University

Fundación Huésped

Merck & Co., Inc., Rahway, NJ, USA (United States)

Assistance Publique – Hôpitaux de Paris

Hans Jaeger is an author at MUC Research (Germany) specializing in antiretroviral therapy, antiviral therapy, and pharmacotherapy.

Publications per year

1988–2019

11

Publications

11

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

François Raffi, Hans Jaeger, Eugenia Quirós-Roldán et al. · The Lancet Infectious Diseases · 2013 · 372 citations

, , +11

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2018 · 145 citations

, , +10

Tryptophan Degradation in Patients Infected by Human Immunodeficiency Virus

Ernst R. Werner, A Hausen, Hans Jaeger et al. · Biological Chemistry Hoppe-Seyler · 1988 · 82 citations

, , +11

Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection

Guenther Schmutz, Mark Nelson, Thomas A. Lutz et al. · AIDS · 2006 · 81 citations

, , +17

Dolutegravir Monotherapy as Treatment De-Escalation in HIV-Infected Adults with Virological Control: DoluMono Cohort Results

Celia Oldenbuettel, Eva Wolf, Ayla Ritter et al. · Antiviral Therapy · 2016 · 40 citations

, , +17

1–5 of 11